Pulmonary Hypertension Pharmacology

Pulmonary arterial hypertension is defined hemodynamically as a mean pulmonary arterial pressure greater than 20 mmHg at rest, measured by right heart catheterization, with a pulmonary arterial wedge pressure at or below 15 mmHg and a pulmonary vascular resistance greater than 2 Wood units. These thresholds, updated in the 2022 European Society of Cardiology and European Respiratory Society guidelines, distinguish precapillary from postcapillary pulmonary hypertension. Pulmonary arterial hypertension is classified as Group 1 in the World Health Organization clinical classification — pulmonary arterial hypertension-specific therapies are approved for Group 1 only and must not be applied across other groups without careful clinical evaluation.

The underlying pathology involves three simultaneous processes in the small pulmonary arteries. First, endothelial dysfunction produces an imbalance between vasodilatory mediators — primarily prostacyclin and nitric oxide — and vasoconstrictive mediators, primarily endothelin-1, shifting vascular tone toward sustained constriction. Second, abnormal proliferation of pulmonary arterial smooth muscle cells and endothelial cells produces intimal thickening, medial hypertrophy, and adventitial fibrosis — collectively termed pulmonary vascular remodeling. Third, in situ microthrombosis within obliterated vessels further increases pulmonary vascular resistance.

The net result is a fixed, progressive increase in pulmonary vascular resistance that forces the right ventricle to generate ever-higher pressures to maintain forward cardiac output. The right ventricle hypertrophies initially but eventually dilates and fails as it cannot sustain the chronic pressure overload. Right ventricular failure is the mechanism of death in most patients with pulmonary arterial hypertension. All three approved pharmacological classes act by targeting the endothelial imbalance — not the structural remodeling, which is largely irreversible.

Endothelin-1 acts on two receptor subtypes with opposing functions in the pulmonary vasculature. Endothelin A receptors on pulmonary arterial smooth muscle cells mediate vasoconstriction and proliferation — blocking them is therapeutically desirable. Endothelin B receptors on pulmonary vascular endothelial cells mediate vasodilation (by stimulating nitric oxide and prostacyclin release) and endothelin clearance — blocking them is therapeutically counterproductive. This distinction drives the pharmacological debate between dual endothelin A/B receptor antagonism versus selective endothelin A receptor antagonism.

Bosentan is a dual endothelin A and B receptor antagonist — it blocks both subtypes. Despite the theoretical concern about endothelin B blockade, bosentan demonstrated clear clinical benefit in the BREATHE-1 trial and was the first oral agent approved for pulmonary arterial hypertension. Ambrisentan is a selective endothelin A receptor antagonist, preserving endothelin B-mediated vasodilation and clearance. Macitentan is a dual endothelin A and B antagonist with high tissue penetency and sustained receptor binding; the SERAPHIN trial demonstrated that macitentan reduced the composite morbidity and mortality endpoint compared with placebo, providing the strongest evidence base among endothelin receptor antagonists.

Hepatotoxicity is a class-wide concern for endothelin receptor antagonists. Bosentan has the most pronounced hepatotoxic signal — elevated liver enzymes occur in approximately 10% of patients, and monthly liver function test monitoring is required. Ambrisentan and macitentan have substantially lower hepatotoxicity rates, but liver enzyme monitoring is still recommended. Teratogenicity is an absolute contraindication for all endothelin receptor antagonists — animal studies demonstrate major teratogenic effects, and two reliable forms of contraception are required for women of childbearing potential throughout treatment. Peripheral edema and anemia (from fluid retention and hemodilution) are additional class effects. Bosentan is also a significant inducer of cytochrome P450 3A4 and 2C9, reducing plasma concentrations of warfarin, statins, cyclosporine, and other medications.

The AMBITION trial compared upfront combination therapy with ambrisentan plus tadalafil against either drug as monotherapy in treatment-naive patients with pulmonary arterial hypertension. The combination arm reduced the risk of the primary composite endpoint (clinical failure events) by 50% relative to monotherapy pooled, demonstrating that two-drug upfront therapy is superior to sequential addition of a second drug. This trial established dual upfront combination therapy as the standard initial approach for most newly diagnosed pulmonary arterial hypertension patients.

Triple therapy — adding a prostacyclin-pathway agent to an established dual combination — is used in patients who remain at intermediate or high risk after optimized dual therapy. The GRIPHON trial supporting selexipag enrolled patients predominantly on background endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor therapy, providing the evidence base for triple combination regimens.

Current guidelines use a three-strata risk assessment (low, intermediate, high) based on clinical parameters including World Health Organization functional class, six-minute walk distance, brain natriuretic peptide, right atrial pressure, cardiac index, and mixed venous oxygen saturation. The treatment goal is to achieve and maintain low-risk status. Patients assessed as intermediate or high risk at any follow-up visit require treatment escalation. This treat-to-target approach — borrowed conceptually from oncology and rheumatology — prevents the common error of accepting stable but suboptimal disease as a satisfactory outcome in a condition with relentlessly progressive underlying pathology.